CD8A and neoplasm: In animal models, lenvatinib, a multiple receptor tyrosine kinase inhibitor, was demonstrated to reduce tumour-associated macrophages and increase the percentage of activated CD8+ T cells secreting interferon (IFN)-γ + and granzyme B (GzmB).